Murray Grossman1. 1. Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Abstract
BACKGROUND: Primary progressive aphasia (PPA) is a progressive disorder of language that is increasingly recognised as an important presentation of a specific spectrum of neurodegenerative conditions. AIMS: In an era of etiologically specific treatments for neurodegenerative conditions, it is crucial to establish the histopathologic basis for PPA. In this review, I discuss biomarkers for identifying the pathology underlying PPA. MAIN CONTRIBUTION: Clinical syndromes suggest a probabilistic association between a specific PPA variant and an underlying pathology, but there are also many exceptions. A considerable body of work with biomarkers is now emerging as an important addition to clinical diagnosis. I review genetic, neuroimaging and biofluid studies that can help determine the pathologic basis for PPA. CONCLUSIONS: Together with careful clinical examination, there is great promise that supplemental biomarker assessments will lead to accurate diagnosis of the pathology associated with PPA during life and serve as the basis for clinical trials in this spectrum of disease.
BACKGROUND:Primary progressive aphasia (PPA) is a progressive disorder of language that is increasingly recognised as an important presentation of a specific spectrum of neurodegenerative conditions. AIMS: In an era of etiologically specific treatments for neurodegenerative conditions, it is crucial to establish the histopathologic basis for PPA. In this review, I discuss biomarkers for identifying the pathology underlying PPA. MAIN CONTRIBUTION: Clinical syndromes suggest a probabilistic association between a specific PPA variant and an underlying pathology, but there are also many exceptions. A considerable body of work with biomarkers is now emerging as an important addition to clinical diagnosis. I review genetic, neuroimaging and biofluid studies that can help determine the pathologic basis for PPA. CONCLUSIONS: Together with careful clinical examination, there is great promise that supplemental biomarker assessments will lead to accurate diagnosis of the pathology associated with PPA during life and serve as the basis for clinical trials in this spectrum of disease.
Authors: K A Josephs; D S Knopman; J L Whitwell; B F Boeve; J E Parisi; R C Petersen; D W Dickson Journal: Neurology Date: 2005-08-23 Impact factor: 9.910
Authors: E D Roberson; J H Hesse; K D Rose; H Slama; J K Johnson; K Yaffe; M S Forman; C A Miller; J Q Trojanowski; J H Kramer; B L Miller Journal: Neurology Date: 2005-09-13 Impact factor: 9.910
Authors: Penelope G Foulds; Yvonne Davidson; Manjari Mishra; David J Hobson; Kirsty M Humphreys; Mark Taylor; Nancy Johnson; Sandra Weintraub; Haruhiko Akiyama; Tetsuaki Arai; Masato Hasegawa; Eileen H Bigio; Fiona E Benson; David Allsop; David M A Mann Journal: Acta Neuropathol Date: 2009-10-13 Impact factor: 17.088
Authors: Ian R A Mackenzie; Manuela Neumann; Eileen H Bigio; Nigel J Cairns; Irina Alafuzoff; Jillian Kril; Gabor G Kovacs; Bernardino Ghetti; Glenda Halliday; Ida E Holm; Paul G Ince; Wouter Kamphorst; Tamas Revesz; Annemieke J M Rozemuller; Samir Kumar-Singh; Haruhiko Akiyama; Atik Baborie; Salvatore Spina; Dennis W Dickson; John Q Trojanowski; David M A Mann Journal: Acta Neuropathol Date: 2008-11-18 Impact factor: 17.088
Authors: Alan M Pittman; Amanda J Myers; Jaime Duckworth; Leslie Bryden; Melissa Hanson; Patrick Abou-Sleiman; Nicholas W Wood; John Hardy; Andrew Lees; Rohan de Silva Journal: Hum Mol Genet Date: 2004-04-28 Impact factor: 6.150
Authors: Alberto Lleó; David J Irwin; Ignacio Illán-Gala; Corey T McMillan; David A Wolk; Edward B Lee; Vivianna M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman Journal: JAMA Neurol Date: 2018-06-01 Impact factor: 18.302
Authors: Jara Stalpaert; Marijke Miatton; Anne Sieben; Tim Van Langenhove; Pieter van Mierlo; Miet De Letter Journal: Front Hum Neurosci Date: 2021-06-02 Impact factor: 3.169